Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2026-01-02 @ 2:19 PM
Study NCT ID:
NCT03787992
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-11
First Post:
2018-12-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Sponsor:
Allist Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell … | View |
Keywords: